JP2024530315A5 - - Google Patents
Info
- Publication number
- JP2024530315A5 JP2024530315A5 JP2024513277A JP2024513277A JP2024530315A5 JP 2024530315 A5 JP2024530315 A5 JP 2024530315A5 JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024530315 A5 JP2024530315 A5 JP 2024530315A5
- Authority
- JP
- Japan
- Prior art keywords
- ray powder
- crystalline form
- powder diffraction
- diffraction pattern
- morphology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021115718 | 2021-08-31 | ||
| CNPCT/CN2021/115718 | 2021-08-31 | ||
| PCT/CN2022/116084 WO2023030363A1 (en) | 2021-08-31 | 2022-08-31 | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530315A JP2024530315A (ja) | 2024-08-16 |
| JP2024530315A5 true JP2024530315A5 (cg-RX-API-DMAC7.html) | 2025-09-03 |
Family
ID=85410866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513277A Pending JP2024530315A (ja) | 2021-08-31 | 2022-08-31 | Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240317743A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4396180A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024530315A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240054327A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118215660A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022336557A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230314A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311106A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002465A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023030363A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| TW202604488A (zh) | 2024-06-26 | 2026-02-01 | 瑞士商百濟神州I有限責任公司 | 包含索托克拉固體分散體之醫藥調配物及其製備方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2546294T7 (es) * | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| KR101762724B1 (ko) * | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| CN112437772B (zh) * | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2022
- 2022-08-31 MX MX2024002465A patent/MX2024002465A/es unknown
- 2022-08-31 EP EP22863498.6A patent/EP4396180A4/en active Pending
- 2022-08-31 WO PCT/CN2022/116084 patent/WO2023030363A1/en not_active Ceased
- 2022-08-31 CN CN202280058535.7A patent/CN118215660A/zh active Pending
- 2022-08-31 KR KR1020247010341A patent/KR20240054327A/ko active Pending
- 2022-08-31 CA CA3230314A patent/CA3230314A1/en active Pending
- 2022-08-31 JP JP2024513277A patent/JP2024530315A/ja active Pending
- 2022-08-31 IL IL311106A patent/IL311106A/en unknown
- 2022-08-31 AU AU2022336557A patent/AU2022336557A1/en active Pending
-
2024
- 2024-02-27 US US18/589,022 patent/US20240317743A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536960A5 (cg-RX-API-DMAC7.html) | ||
| ES2527768T5 (es) | Sales cristalinas de sitagliptina | |
| CN101068793B (zh) | Hiv整合酶抑制剂的钾盐 | |
| JP4142621B2 (ja) | 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法 | |
| RS55353B2 (sr) | Tenofovir alafenamid hemifumarat | |
| TW202214601A (zh) | Apol1抑制劑之固體形式及其使用方法 | |
| JP2022512824A5 (cg-RX-API-DMAC7.html) | ||
| JP2025508071A5 (cg-RX-API-DMAC7.html) | ||
| TWI377205B (en) | Isoxazoline derivative and novel process for its preparation | |
| IL297041A (en) | Inhibitors of human immunodeficiency virus replication | |
| TW201617315A (zh) | 異吲哚啉酮衍生物 | |
| WO2024206647A1 (en) | Polymorphic forms and salts of a glp-1r agonist | |
| JP2025102940A5 (cg-RX-API-DMAC7.html) | ||
| TW201625549A (zh) | 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 | |
| TWI808069B (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| TW202019406A (zh) | 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法 | |
| WO2019119832A1 (zh) | 用于代谢性疾病治疗的化合物及其制备方法和应用 | |
| JP2005529084A (ja) | 結晶性パレコキシブナトリウム | |
| JP2024001040A5 (cg-RX-API-DMAC7.html) | ||
| CN111592485A (zh) | 盐酸替罗非班及其游离碱的晶型及其制备方法 | |
| JP7448541B2 (ja) | 選択的エストロゲン受容体分解剤の新規な塩 | |
| CN118401525A (zh) | 吡唑并[3,4-d]嘧啶化合物的固体形式 | |
| JP2004530706A (ja) | 純粋な結晶形態にある5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニル及び合成方法 | |
| CA3244893A1 (en) | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4-YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC AND ITS CRYSTALLINE FORMS FOR USE AS A PHARMACEUTICALLY ACTIVE COMPOUND | |
| JP2024520897A5 (cg-RX-API-DMAC7.html) |